imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
erlotinib/mylan f.c.tab 150mg/tab
mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - erlotinib hydrochloride - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 150mg/tab - erlotinib hydrochloride 163,9mg - erlotinib
erlotinib/mylan f.c.tab 100mg/tab
mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - erlotinib hydrochloride - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 100mg/tab - erlotinib hydrochloride 109,27mg - erlotinib
bortezomib/mylan pd.inj.sol 3.5mg/vial
mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - bortezomib - pd.inj.sol (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 3.5mg/vial - bortezomib 3,5mg - bortezomib
bortezomib/mylan pd.inj.sol 1mg/vial
mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - bortezomib - pd.inj.sol (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 1mg/vial - bortezomib 1mg - bortezomib
aerolin 100mcg/dose (br.op.i aer.md.inh
glaxo wellcome a.e.b.e. - salbutamol - ΑΕΡΟΛΥΜΑ ΓΙΑ ΕΙΣΠΝΟΗ, ΣΤΑΘΕΡΩΝ ΔΟΣΕΩΝ - 100mcg/dose (br.op.i - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
varlota 150mg film coated tablets
pharos-pharmaceutical oriented services ltd - erlotinib ΥΔΡΟΧΛΩΡΙΚΉ - film coated tablets - 150mg - 1833196919 - erlotinib hydrochloride - 163.9 mg - erlotinib
varlota 100mg film coated tablets
pharos-pharmaceutical oriented services ltd - erlotinib ΥΔΡΟΧΛΩΡΙΚΉ - film coated tablets - 100mg - 1833196919 - erlotinib hydrochloride - 109.27 mg - erlotinib
varlota 25mg film coated tablets
pharos-pharmaceutical oriented services ltd - erlotinib ΥΔΡΟΧΛΩΡΙΚΉ - film coated tablets - 25mg - 1833196919 - erlotinib hydrochloride - 27.32 mg - erlotinib
xevudy
glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - Άνοσοι οροί και ανοσοσφαιρίνες, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.